201 related articles for article (PubMed ID: 23576099)
1. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.
Hänscheid H; Canzi C; Eschner W; Flux G; Luster M; Strigari L; Lassmann M
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1126-34. PubMed ID: 23576099
[TBL] [Abstract][Full Text] [Related]
2. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.
Lassmann M; Hänscheid H; Chiesa C; Hindorf C; Flux G; Luster M;
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1405-12. PubMed ID: 18491092
[TBL] [Abstract][Full Text] [Related]
3. Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases.
Andersson M; Mattsson S
Front Endocrinol (Lausanne); 2021; 12():634955. PubMed ID: 33776929
[TBL] [Abstract][Full Text] [Related]
4. The EANM guideline on radioiodine therapy of benign thyroid disease.
Campennì A; Avram AM; Verburg FA; Iakovou I; Hänscheid H; de Keizer B; Petranović Ovčariček P; Giovanella L
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3324-3348. PubMed ID: 37395802
[TBL] [Abstract][Full Text] [Related]
5. EANM procedure guidelines for therapy of benign thyroid disease.
Stokkel MP; Handkiewicz Junak D; Lassmann M; Dietlein M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2218-28. PubMed ID: 20625722
[TBL] [Abstract][Full Text] [Related]
6. Pretherapeutic dosimetry before 131I therapy of benign thyroid disease. A clinical practice assessment of dosimetric parameters.
Krohn T; Behrendt FF; Heinzel A; Müller B; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(3):131-6. PubMed ID: 25487217
[TBL] [Abstract][Full Text] [Related]
7. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
9. Guidelines for radioiodine therapy of differentiated thyroid cancer.
Luster M; Clarke SE; Dietlein M; Lassmann M; Lind P; Oyen WJ; Tennvall J; Bombardieri E;
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1941-59. PubMed ID: 18670773
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry prior to I-131-therapy of benign thyroid disease.
Hänscheid H; Lassmann M; Reiners C
Z Med Phys; 2011 Dec; 21(4):250-7. PubMed ID: 21531122
[TBL] [Abstract][Full Text] [Related]
11. EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for
Gear J; Chiesa C; Lassmann M; Gabiña PM; Tran-Gia J; Stokke C; Flux G;
EJNMMI Phys; 2020 Mar; 7(1):15. PubMed ID: 32144574
[TBL] [Abstract][Full Text] [Related]
12. Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD's voxel S values in Graves' disease.
Fujita N; Koshiba Y; Abe S; Kato K
EJNMMI Phys; 2020 Jan; 7(1):6. PubMed ID: 31993828
[TBL] [Abstract][Full Text] [Related]
13. EANM procedure guidelines for therapy with iodine-131.
EANM
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP27-31. PubMed ID: 12723563
[No Abstract] [Full Text] [Related]
14. Improving individualised dosimetry in radioiodine therapy for hyperthyroidism using population biokinetic modelling.
Melgar Pérez J; Orellana Salas A; Santaella Guardiola Y; Antoranz Callejo JC
Phys Med; 2019 Jun; 62():33-40. PubMed ID: 31153396
[TBL] [Abstract][Full Text] [Related]
15. The new EANM paediatric dosage card: additional notes with respect to F-18.
Lassmann M; Biassoni L; Monsieurs M; Franzius C;
Eur J Nucl Med Mol Imaging; 2008 Sep; 35(9):1666-8. PubMed ID: 18574583
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy in benign thyroid disorders. Evaluation of French nuclear medicine practices.
Bernard D; Desruet MD; Wolf M; Roux J; Boin C; Mazet R; Gallazzini C; Calizzano A; Vuillez JP; Allenet B; Fagret D
Ann Endocrinol (Paris); 2014 Sep; 75(4):241-6. PubMed ID: 25156133
[TBL] [Abstract][Full Text] [Related]
17. [Radioiodine therapy for benign thyroid diseases (version 5). German Guideline].
Dietlein M; Grünwald F; Schmidt M; Schneider P; Verburg FA; Luster M
Nuklearmedizin; 2016 Dec; 55(6):213-220. PubMed ID: 27922153
[TBL] [Abstract][Full Text] [Related]
18. The impact of different computational assumptions in
Abuqbeitah M; Sağer S; Demir M; Yeyin N; Akovalı B; Sönmezoğlu K
Med Phys; 2020 Nov; 47(11):5810-5816. PubMed ID: 32969067
[TBL] [Abstract][Full Text] [Related]
19. Benign thyroid disease: what is the role of nuclear medicine?
Sarkar SD
Semin Nucl Med; 2006 Jul; 36(3):185-93. PubMed ID: 16762609
[TBL] [Abstract][Full Text] [Related]
20. Thyroid echogenicity: A clue to precise individual dosimetry in radioiodine therapy of hyperthyroidism.
Marković V; Eterović D; Stipanović P; Punda A
Med Hypotheses; 2011 Feb; 76(2):153-6. PubMed ID: 20889262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
